Clinical Trials Logo

Filter by:
NCT ID: NCT05277922 Completed - Clinical trials for Study Vasodilatory Effects of C21

Effect of C21 on Forearm Blood Flow

Start date: April 28, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the effect of C21 on forearm blood flow by use of strain-gauge venous occlusion plethysmography.

NCT ID: NCT05277532 Recruiting - Overweight Clinical Trials

Effect of Circadian Rhythm and Physical Exercise in Overweight Type 1 Diabetes Patients

Start date: May 18, 2022
Phase: N/A
Study type: Interventional

Cardiometabolic risk in patients with abdominal obesity and type 1 diabetes can be moderated by life style modifications. There is an intimate link between gene regulation and circadian rhythm in mediating response to exercise in a variety of insulin sensitive organs. The aim of this project is to evaluate, by intervention, the interplay of circadian rhythm and high intensity interval training (HIIT) on glucose control and skeletal muscle metabolism in patients with overweight with or without type 1 diabetes (T1D).

NCT ID: NCT05276193 Recruiting - Gambling Disorder Clinical Trials

GamReg Sweden - Quality Register for Gambling and Gaming Disorders

Start date: April 15, 2019
Phase:
Study type: Observational [Patient Registry]

This is a quality register for the monitoring of clinical assessment and treatment for gambling disorder and gaming disorder in Swedish health care. This register is held by Region Skåne, the health care organization of Skåne in southern Sweden, and administered by Register center South, which is associated with health care services in the southern regions of Sweden (the establishment of quality registers in Swedish health care relies upon a national legislation). Quality registers by themselves do not represent formal research projects. However, future research projects can use quality registers, such as the present one, as a data source for future research projects in case they are approved by an ethics authority. Clinical study variables collected in the register include the following (examples): - gender, age, occupation, living conditions - if applicable, types of gambling associated with the treatment needs - if applicable, type of problematic video gaming - type of referral to the present treatment contact - treatment history in psychiatry, social services, enforcement agency - history of suicidal behavior - alcohol and drugs problems requiring assessment or treatment - violence victimization - type of treatment provided to the patient

NCT ID: NCT05276180 Active, not recruiting - Occupational Health Clinical Trials

Evaluation of Interventions for Safe Patient Handling and Movement in the Healthcare Sector

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

There are several situations in the workplace in which both healthcare workers and patients are at risk of injury. Frequent patient transfers, heavy lifting and patient mobilization are proven risk factors for musculoskeletal disorders among healthcare workers. Falls and patient transfers are frequently reported causes of patient injuries. Swedish occupational safety and health legislation and the Patient Safety Act require employers to provide good, safe care and to conduct risk assessments to prevent risks and injuries in the healthcare sector. It has been suggested that a combination of workplace interventions is needed to facilitate safe patient handling and movement and to prevent musculoskeletal disorders and injuries among healthcare workers and patients. The main aim of the cluster randomized and controlled trial (RCT) is to evaluate a multifactorial intervention strategy that includes risk assessment instruments as well as guidelines and training. This strategy will be compared with a single intervention strategy for safe patient handling and movement in workplaces in the Swedish regional and municipal healthcare system. All healthcare workers in the care units recruited to this RCT will be invited to participate. The study will evaluate the intervention strategies with regard to primary outcome measures given equal priority according to a hybrid 2 design of the RCT. These are: 1) the implementation process (acceptability, appropriateness and feasibility), here called the implementation outcome, and 2) the effect of the applied strategies (measured with regard to the workplace safety climate and additional questions about safety for patient handling and movement), here called intervention effectiveness. This RCT is part of the Swedish Patient and Workers Safety Study (PAWSS). The aim of the PAWSS project is to contribute to a regional and municipal healthcare that is evidence-based and organized for both patient safety and a safe working environment for healthcare workers. The long-term goal is to facilitate safe patient handling and movement practices which prevent both care injuries and work injuries.

NCT ID: NCT05276128 Completed - Obesity Clinical Trials

Effects of Plant Based Lipids on Glucose Regulation and Cognitive Variables

Start date: March 20, 2022
Phase: N/A
Study type: Interventional

The overall goal is to increase the knowledge that can be used for the development of food products with anti-diabetic properties, with the purpose to facilitate healthier food choices for people. More specifically the primary purpose of this project is to evaluate effects in healthy humans on acute postprandial glucose regulation of plant based lipids. Due to the tight connection between cardiometabolic health and cognitive functions, a secondary issue is to investigate effects of test foods on cognitive test variables and mood parameters.

NCT ID: NCT05275738 Recruiting - Glaucoma Clinical Trials

The Glaucoma Nicotinamide Trial

TGNT
Start date: May 18, 2022
Phase: N/A
Study type: Interventional

The Glaucoma Nicotinamide Trial (TGNT) is a prospective, randomized, placebo-controlled double-masked clinical trial composed of two cohorts; The Swedish Glaucoma Nicotinamide Trial (SGNT) and the Vitamin B3 In Glaucoma Study (VBIGS). Patients with open-angle glaucoma (OAG) will be randomized to receive either Nicotinamide or placebo through block randomization stratified by glaucoma subtype with a 1:1 allocation.

NCT ID: NCT05275257 Withdrawn - Clinical trials for Urinary Incontinence

Can the Use of Uricap Female Device Lead to Better Care for Women > 75+Years?

U-PROTECT
Start date: April 2022
Phase: N/A
Study type: Interventional

The purpose of the study is to evaluate if Uricap Female, an uridome for women, can be used instead of traditional incontinence aids to treat urinary incontinence (UI) among women 75 years and older.

NCT ID: NCT05274269 Completed - Cystic Fibrosis Clinical Trials

Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation

Start date: May 9, 2022
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy, pharmacodynamics (PD) and safety of ELX/TEZ/IVA in participants 6 years of age and older with a non-F508del ELX/TEZ/IVA-responsive cystic fibrosis transmembrane conductance regulator gene (CFTR) mutation.

NCT ID: NCT05271942 Recruiting - Cataract Clinical Trials

Tilt and Tumble vs Divide and Conquer - a Unique Comparison of the Two Cataract Surgery Methods

Start date: September 8, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to compare two different methods used during cataract surgery to remove the lens in the eye.

NCT ID: NCT05271110 Not yet recruiting - Clinical trials for Disseminated Pancreatic Cancer

Surgery for Liver Metastases From PDAC

ScanPan1
Start date: March 2022
Phase: N/A
Study type: Interventional

Dissemination from pancreatic ductal adenocarcinoma (PDAC) occurs in clinical practice either in the form of recurrence after initial treatment with curative intent resection (metachronous) or more frequently prevails already at the time of diagnosis (synchronous). Traditionally, metastatic pancreatic cancer (mPDAC) is considered not to be eligible for meaningful aggressive therapies to be implemented. However, with the development of local as well as more effective systemic therapeutic regimens a variety of clinical situations have to be reevaluated. For instance, recent reports have indicated an option for maintained or even prolonged survival after resections and/or ablations of oligometastatic pancreatic cancer (OMDPDAC), as represented by a single or few liver metastasis (es). These reports are burdened by methodological weaknesses such as being retrospective, single institution and reporting only from highly selected case series. A common denominator of acceptable outcome is, however, that all metastatic lesions have been preoperatively treated and responded to chemotherapy, indicating an advantageous tumor biology. Hence an unbiased approach, including neo-adjuvant chemotherapy before any aggressive local treatment must be explored to the updated management opportunities in terms of assessing the prevalence, safety, feasibility, tolerability and possible disease control options. Primary objective (clinical): To prospectively investigate (on an intention to treat basis) the safety, feasibility, tolerability and clinical outcomes of all patients with PDAC presenting with limited metastatic disease, where a treatment option can be launched with the ambition of local disease control and eventually better survival. The cohorts to be included are: Primary cohort: Patients with liver limited (metachronous and synchronous) metastasis(es) due to PDAC. This cohort is further subdivided to: Limited liver disease. Extended liver disease. Secondary cohort: Patients with OMDPDAC and at least one extrahepatic manifestation of PDAC. Secondary objective (translational) is to improve the understanding of PDAC liver metastases biology by studying the mechanistic aspects of metastases invasion as well as intra- and peri-tumoral liver metastatic niche, and by charting the cellular composition of liver metastases on single cell level with a focus on the impact of cellular interactions on tumor cell growth and differentiation. Furthermore, the study aims to identify blood-based biomarkers of response to oncologic/surgical treatment.